



RENTECH

THE NEPHRO-PEN

WRITE YOUR FUTURE WITH US

Start-Up Business Plan

Wakeland High School

10700 Legacy Dr, Frisco, TX 75034

Sarah Sonny, Natalie Tebeaux, Samantha Stein

04/23/22

TABLE OF CONTENTS

I.	Executive Summary	1
II.	Problems	2
III.	Customer Segments	3
IV.	Unique Value Proposition	4
V.	Solutions	4-5
VI.	Channels	5-6
VII.	Revenue Streams	6
VIII.	Cost Structure	6-8
IX.	Key Metrics	9
X.	Competitive Advantage	9
XI.	Conclusion	10
XII.	Bibliography	10

EXECUTIVE SUMMARY

COMPANY OVERVIEW

The Nephro-Pen is a new and innovative product brought to consumers by our company RenTech, where we specialize in technology to treat renal diseases. The Nephro-Pen uses pluripotent stem cells harvested from the patient to create a patient-specific surgical pen with syringe-like capabilities. In just three weeks, cells are developed and identified creating a device that can instantly heal damaged kidney tissue. RenTech started with just an idea, and now we have brought a new device with the most up-to-date technology, innovation, and efficiency than ever before. From drawing diagrams out on a whiteboard, to our first meeting to see if this could really become true, The Nephro-Pen is the best thing to come from medical technology to-date.

PROBLEMS



Kidney Dialysis



Kidney Transplant



Donor Shortages

SOLUTIONS



No Need for Dialysis



No Need for Transplant



Complete Removal

CUSTOMER SEGMENTS

Primary

CKD Patients
65+

Secondary

Diabetic CKD
Patients

Nephrologists

*to build trust in
the medical field

Market Size

4% of Primary & 1% of Secondary

CHANNELS



Direct
Distribution



Website



Google




Medical
Journals

REVENUE STREAMS

Net Income:
\$550,000,000

COST STRUCTURE



KEY METRICS



Gross
Margin



Customer
Acquisition



Net-Profit
Margin

COMPETITIVE ADVANTAGE

Cost Effective

Time Efficient

Regeneration

Patient-Specific



Start-Up
Costs



Break-Even



Taxes

UNIQUE VALUE PROPOSITION

An innovative alternative to today's kidney disease treatments that utilizes pluripotent stem cells and 1080S medical grade stainless steel to rebuild damaged tissue.

REQUEST FOR FINANCING

RenTech is asking for a capital investment of 15 million dollars for a 10% stake equity in our company RenTech: The Nephro-Pen.

CONCLUSION

RETURN OF INVESTMENT

Over the course of one year, the investor will have an investment gain of \$40,007,813.30 and a return of investment of 266.72%.